News Archive

Neither prescription volume nor approval rates for PCSK9 inhibitors increased following the release of results from two large outcomes trials that demonstrated safety and effectiveness of this nove

In a recent editorial, DCRI faculty call for improved heart failure trial enrollment, as well as modifications to the infrastructure used to evaluate whether treatments work in real-world settings.

Two DCRI researchers contributed to a study that points to a potential early warning sign for increased risk of cardiovascular disease.

A recent study led by the DCRI leveraged real-world data to shed new light on resuscitation for patients on maintenance dialysis when they experience in-hospital cardiac arrest.

Evidence from a recently completed DCRI-led clinical trial supports the hypothesis that an investigational digital therapeutic may be an effective treatment for children with ADHD.

The EXSCEL trial, which explored the impact of exenatide on major cardiovascular events in patients with Type 2 diabetes, has also published nearly a dozen secondary manuscripts on a range of topic

In response to a recent study that found the majority of cardiovascular patients are eligible for at least one of 12 novel secondary prevention therapies, representatives from the DCRI urge a focus on implementation of these therapies into clinical practice. The wide range of new therapies for cardiovascular secondary prevention raises questions about the best way to use these therapies in clinical practice and underscores the need for novel approaches to implement these therapies into routine patient care.

The observational study found that amongst acute ischemic stroke patients treated with intravenous tissue plasminogen activator, patients who had experienced a previous stroke within the past two w

The HARMONEE trial is part of the Harmonization by Doing program, which aims to create a uniform pathway for clinical development in the U.S. and Japan.

A new analysis from the DCRI showed that 35 percent of direct costs related to musculoskeletal pain were attributable to about 4 percent of patients who were persistent high-cost utilizers.